July 17, 2013
(Nasdaq: CYNO), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced that the company will release its second-quarter 2013 financial results before the market opens on
Wednesday, July 31
and host a conference call for investors and analysts that day at
9:00 a.m. ET
On the call, Chairman and Chief Executive Officer
and Executive Vice President, Chief Operating Officer and Chief Financial Officer
will discuss Cynosure's financial results, as well as the company's business outlook and strategy.
Those who wish to listen to the conference call webcast should visit the "Investor Relations" section of the company's website at
. The live call also can be accessed by dialing (877) 709-8155 or (201) 689-8881. If you are unable to listen to the live call, the webcast will be archived on the company's
About Cynosure, Inc.
develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical professionals to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, treat toe fungus and ablate sweat glands. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, Q-switched lasers and intense pulsed light. Cynosure sells its products globally under the Cynosure, Palomar and ConBio brand names through a direct sales force in
the United States
and Korea, and through international distributors in approximately 100 other countries. For corporate or product information, visit Cynosure's website at
Vice President Sharon Merrill Associates 617-542-5300
SOURCE Cynosure, Inc.